Table I.

Patient characteristics.

Pt	Sub‐type	Karyotype	Age at diagnosis (years)	Gender	Disease status at biopsy	MRD Risk†	Treatment protocol
1	c‐ALL	Hyperdiploidy	7	M	D	High	UKALL 2003
2	Pre B	t(12;21)	2	F	D	Low	UKALL 2003
3	Pre B	−1	2	F	D	Low	UKALL 2003
4	Pre B	t(9;22)	15	M	D	Low	UKALL 2011
5	Pre B	Hyperdiploidy	2	M	D	Low	UKALL 2003
6	Pre B	46XY	9	M	D	High	UKALL 2011
7	Pre B	t(12;21)	2	F	D	Low	UKALL 2011
8	c‐ALL	t(12;21)	4	M	D	ND	UKALL 2011
9	Pre B	−9, +10, −18	2	F	D	High	UKALL 2003
10	Pre B	46XY	14	F	D	Int	UKALL 2011
11	Pre B	+7, −9, −Y	3	M	D	Low	UKALL 2011
12	c‐ALL	t(12;21)	7	F	D	Low	UKALL 2011
13	c‐ALL	+5	5	F	D	Int	UKALL 2011
14	Pro B	11q23 rearr	15	F	D	High	UKALL 2011
15	Pro B	11q23 rearr	17	F	D	Int	UKALL 2011
16	Pre B	t(12;21)	5	M	D	Low	UKALL 2011
17	Pre B	t(12;21)	3	M	D	Low	UKALL 2011
18	Pre B	PDGFRB rearr, −12p	8	F	D	High	UKALL 2011
19	Pre B	t(1;19)	12	M	D	Low	UKALL 2011
20	c‐ALL	+5	17	M	D	Low	UKALL 2011
21	T‐ALL	+4, +9	15	M	D	High	UKALL 2003
22	T‐ALL	t(11;14)	2	M	R	Low	UKALL 2003
23	T‐ALL	46XY	17	M	D	High	UKALL 2003
24	T‐ALL	−3, −6, −11, +1	2	F	D	ND	UKALL 2011
25	T‐ALL	t(1;14)	3	M	D	Int	UKALL 2011
26	T‐ALL	46XY	6	M	D	Low	UKALL 2011
27	T‐ALL	−4, −9	9	M	D	Low	UKALL 2011
28	T‐ALL	46XY	7	M	D	Int	UKALL 2011
29	T‐ALL	21q22 rearr	3	M	D	ND	UKALL 2011
30	T‐ALL	+7, +9, +14, +mar	4	M	D	Low	UKALL 2011
31	T‐ALL	+ABL1	10	M	D	Int	UKALL 2011

D, diagnosis; Int, intermediate; ND, not determined; R, relapse. ALL, acute lymphoblastic leukaemia; c ‐ALL, common ALL; pre B, B‐cell ALL; pro B, B‐cell ALL; T‐ALL, T‐cell ALL. UKALL 2003; UKALL 2011.

^†MRD risk status at day 29 for UKALL 2003 and at week 14 for UKALL 2011.